FFR or OCT Guidance to RevasculariZe Intermediate Coronary Stenosis Using Angioplasty

NCT ID: NCT01824030

Last Updated: 2013-04-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Whether to revascularize patients with angiographically-intermediate coronary lesions (AICL) is a major clinical issue. Intravascular techniques (assessing either the anatomy or the functional effect of coronary stenoses) are routinely used to better characterize coronary lesions. Among these,fractional flow reserve (FFR) provides validated functional insights while optical coherence tomography (OCT) provides high resolution anatomic imaging. Both techniques may be applied to guide decisions regarding the opportunity to revascularize patients with AICL and to optimize the result of percutaneous coronary intervention (PCI). We aim to compare the clinical and the economical impact of FFR versus OCT guidance in the percutaneous management of patients with AICL.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FFR guided PCI arm

Patients with angiographic intermediate coronary artery stenosis randomized to FFR assessment. PCI performed only if FFR ≤ 0.80

Group Type ACTIVE_COMPARATOR

FFR guided PCI

Intervention Type DEVICE

FFR to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention

OCT guided PCI arm

Patients with angiographic intermediate coronary artery stenosis randomized to OCT. PCI will be performed if:

1. percentage area stenosis ≥75 %
2. percentage area stenosis between 50 and 75% and minimal lumen area \<2.5 mm2
3. percentage area stenosis between 50 and 75% and major plaque ulceration

Group Type ACTIVE_COMPARATOR

OCT guided PCI

Intervention Type DEVICE

OCT to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FFR guided PCI

FFR to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention

Intervention Type DEVICE

OCT guided PCI

OCT to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* single vessel disease with an intermediate coronary artery stenosis
* multivessel disease with multiple intermediate coronary artery stenosis only
* multivessel disease with already treated angiographically critical stenosis and at least one intermediate coronary artery stenosis

Exclusion Criteria

* age \<18 years or impossibility to give informed consent,
* female sex with child-bearing potential,
* life expectancy of less than 12 months or factors making clinical follow-up difficult (no fixed address, etc),
* poor cardiac function as defined by left ventricular global ejection fraction ≤ 30%
* recent (\< 7 days) ST-segment elevation myocardial infarction
* recent (\< 48 hours) Non ST-segment elevation myocardial infarction
* prior ST-segment elevation myocardial infarction in the territory supplied by the vessel with the intermediate stenosis under investigation
* severe myocardial hypertrophy (interventricular septum thickness \> 15 mm, ECG Sokolow's criteria fulfilled)
* severe valvular heart disease
* significant platelet count alteration (\<100,000 cells/mm3 or \> 700,000 cells/mm3)
* gastrointestinal bleeding requiring surgery or blood transfusions within 4 previous weeks
* history of clotting pathology
* known hypersensitivity to aspirin, heparin, contrast dye
* advance renal failure with glomerular filtration rate \< 30 ml/min
* lesions in coronary artery bypass grafts
* multivessel disease requiring coronary aortic bypass graft intervention
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Catholic University of the Sacred Heart

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Francesco Burzotta

MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Francesco Burzotta, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Università Cattolica del Sacro Cuore, Roma

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Policlinico A. Gemelli. Università Cattolica del Sacro Cuore

Rome, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Francesco Burzotta, MD, PhD

Role: CONTACT

+39 3494295290

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Francesco Burzotta, MD, PhD

Role: primary

349-429-5290 ext. +39

References

Explore related publications, articles, or registry entries linked to this study.

Aurigemma C, Ding D, Tu S, Li C, Yu W, Li Y, Leone AM, Romagnoli E, Vergallo R, Maino A, Trani C, Wijns W, Burzotta F. Three-Year Clinical Impact of Murray Law-Based Quantitative Flow Ratio and OCT- or FFR-Guidance in Angiographically Intermediate Coronary Lesions. Circ Cardiovasc Interv. 2024 May;17(5):e013191. doi: 10.1161/CIRCINTERVENTIONS.123.013191. Epub 2024 Apr 25.

Reference Type DERIVED
PMID: 38660794 (View on PubMed)

Ding D, Tu S, Li Y, Li C, Yu W, Liu X, Leone AM, Aurigemma C, Romagnoli E, Vergallo R, Trani C, Wijns W, Burzotta F. Quantitative flow ratio modulated by intracoronary optical coherence tomography for predicting physiological efficacy of percutaneous coronary intervention. Catheter Cardiovasc Interv. 2023 Jul;102(1):36-45. doi: 10.1002/ccd.30681. Epub 2023 May 12.

Reference Type DERIVED
PMID: 37172214 (View on PubMed)

Burzotta F, Leone AM, Aurigemma C, Zambrano A, Zimbardo G, Arioti M, Vergallo R, De Maria GL, Cerracchio E, Romagnoli E, Trani C, Crea F. Fractional Flow Reserve or Optical Coherence Tomography to Guide Management of Angiographically Intermediate Coronary Stenosis: A Single-Center Trial. JACC Cardiovasc Interv. 2020 Jan 13;13(1):49-58. doi: 10.1016/j.jcin.2019.09.034.

Reference Type DERIVED
PMID: 31918942 (View on PubMed)

Leone AM, Burzotta F, Aurigemma C, De Maria GL, Zambrano A, Zimbardo G, Arioti M, Cerracchio E, Vergallo R, Trani C, Crea F. Prospective Randomized Comparison of Fractional Flow Reserve Versus Optical Coherence Tomography to Guide Revascularization of Intermediate Coronary Stenoses: One-Month Results. J Am Heart Assoc. 2019 Aug 6;8(15):e012772. doi: 10.1161/JAHA.119.012772. Epub 2019 Jul 23.

Reference Type DERIVED
PMID: 31331219 (View on PubMed)

Burzotta F, Leone AM, De Maria GL, Niccoli G, Coluccia V, Pirozzolo G, Saffioti S, Aurigemma C, Trani C, Crea F. Fractional flow reserve or optical coherence tomography guidance to revascularize intermediate coronary stenosis using angioplasty (FORZA) trial: study protocol for a randomized controlled trial. Trials. 2014 Apr 23;15:140. doi: 10.1186/1745-6215-15-140.

Reference Type DERIVED
PMID: 24758510 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

6261/13

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.